Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Degarelix versus leuprolide for cardiovascular safety in prostate cancer with cardiovascular disease
2017-002495-20Phase 3Completed
- Sponsor
- Ferring Pharmaceuticals
- Start
- Dec 2017
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial in prostate cancer (PCa) comparing Degarelix arm with Leuprolide arm (2 arms). Primary endpoints: Time to first major adverse cardiovascular event and Major adverse cardiovascular event composite. Started Dec 2017; status: completed.
02
Drugs
degarelixleuprolide
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on 2017-002495-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-002495-20.